NewAmsterdam Pharma Company N.V. (NAMS) Financials
NAMS Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 704.5 million | 73.0 million |
| March 31, 2026 | 732.6 million | 67.4 million |
| Dec. 31, 2025 | 769.3 million | 85.9 million |
| Sept. 30, 2025 | 786.4 million | 58.4 million |
NAMS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -69.9 million | 36.4 million |
| March 31, 2026 | -30.6 million | 18.0 million |
| Dec. 31, 2025 | -41.0 million | 14.0 million |
| Sept. 30, 2025 | -32.8 million | 15.0 million |
NAMS Net Income
No data available :(
NAMS Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 633.9 million | - | 82000 |
| March 31, 2026 | 636.1 million | - | 23000 |
| Dec. 31, 2025 | 636.2 million | 66000 | 202000 |
| Sept. 30, 2025 | 702.9 million | 85000 | 266000 |
NAMS Shares Outstanding
NAMS Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 118000 | 41.7 million | 26.9 million | - |
| March 31, 2026 | 38000 | 37.5 million | 23.5 million | - |
| Dec. 31, 2025 | 100000 | 38.6 million | 27.4 million | - |
| Sept. 30, 2025 | 42000 | 31.0 million | 24.5 million | - |
NAMS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 3.7 million | - |
| March 31, 2026 | 3.0 million | 500000 |
| Dec. 31, 2025 | 32000 | 59000 |
| Sept. 30, 2025 | 348000 | 64000 |
NAMS
Price: $27.91
52 week price:
Earnings Per Share: -2.16 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 3.2 billion